IND Applications approved by the U.S. FDA and China CDE for the First EpCAM CAR-T Targeted at Advanced Solid Tumors February 26, 2024
Dragonfly Announces Clinical Collaboration Exploring Combinations of DF1001 HER-2 TriNKET® with Trodelvy® in two Cancer Indications February 26, 2024
Astellas and Kelonia Therapeutics Enter into Research and License Agreement to Develop Novel Immuno-Oncology Therapeutics February 26, 2024
Erasca Announces Two Clinical Trial Collaboration & Supply Agreements for Trametinib to Evaluate Naporafenib Combination in SEACRAFT-1 & SEACRAFT-2 Trials February 26, 2024
US FDA approval of Onivyde® (Irinotecan Liposome Injection) + NALIRIFOX for 1L mPDAC triggers a $225M milestone payment from Ipsen to Merrimack February 26, 2024
ProfoundBio Raises $112 Million in Oversubscribed Series B Equity Financing to Advance its Clinical-Stage ADC Pipeline February 26, 2024
Novartis to strengthen oncology pipeline with agreement to acquire MorphoSys AG for EUR 68 per share or an aggregate of EUR 2.7bn in cash February 26, 2024
Medigene announces indication selection for the clinical development of its TCR-T therapy program in solid tumors February 26, 2024
BioNTech and Autolus Announce Strategic CAR-T Cell Therapy Collaboration to Advance Pipeline and Expand Late-Stage Programs February 26, 2024
Numab Therapeutics and Ono Pharmaceutical Announce an Option and Collaboration Agreement to Develop Multi-specific Antibody NM49 for Treatment of Cancer February 26, 2024
Radiomedix and Orano Med Initiate Ph 2 Multi-Center Trial of Alphamedix™ for Targeted Alpha-Emitter Therapy of Neuroendocrine Cancers February 26, 2024
Nanobiotix Announces Achievement of $20M Development Milestone Payment Related to Ongoing Global Ph 3 Head and Neck Cancer Study February 26, 2024
Nascent Biotech and Manhattan BioSolutions Collaborate to Explore Pritumumab Antibody-Drug Conjugates February 26, 2024
Jazz Pharmaceuticals Enters Definitive Agreement with Redx Pharma to Acquire Global Rights to KRAS Inhibitor Program February 26, 2024
LAVA Therapeutics Announces Collaboration with Merck to Evaluate LAVA-1207 in Combination with KEYTRUDA January 31, 2024
MaxCyte Signs Strategic Platform License with Imugene to Advance their Cancer Immunotherapy Programs January 31, 2024
UroGen Secures Exclusive License from medac GmbH to Develop a Next-Generation Novel Mitomycin-Based Formulation for Urothelial Cancers January 25, 2024
Accurus Biosciences and ImmPACT Bio Enter into an Exclusive Global License Agreement for a Potentially Best-in-Class CLDN18.2 Antibody January 25, 2024
Ferring announces full availability of ADSTILADRIN® (nadofaragene firadenovec -vncg) in the U.S. January 25, 2024
AbbVie and Umoja Biopharma Announce Strategic Collaboration to Develop Novel In-Situ CAR-T Cell Therapies January 18, 2024
